OpenAI teams with Novo Nordisk
OpenAI has signed a partnership with Novo Nordisk to apply its models to drug discovery and delivery workflows, aiming to speed analysis of large biological datasets. Novo also won UK approval for a higher 7.2mg Wegovy dose, highlighting concurrent commercial and regulatory movement in pharma ( ).
Drug discovery starts with huge biology datasets, and Novo Nordisk said on April 14 it will use OpenAI’s models to search them faster across its business. (investegate.co.uk) Novo said the partnership will apply OpenAI tools from early drug discovery through manufacturing and commercial operations, with “strict data governance and human oversight” built into the setup. (investegate.co.uk) The company said the goal is to analyze complex biological data, identify new treatment candidates, and cut the time between research and patient use. Reuters reported the announcement on Tuesday, April 14, as Novo tries to regain momentum in the weight-loss drug market. (cnbc.com) (thestar.com.my) In plain terms, these systems work like pattern-finding software for lab and patient data: they can sort through millions of measurements to flag molecules, targets, or manufacturing steps for scientists to check. Novo said it will also use the deal to upskill employees, not just automate research tasks. (investegate.co.uk) The timing matters for Novo because its obesity and diabetes franchise is under pressure from Eli Lilly, which has gained ground in the weight-loss market. Reuters said Novo has fallen behind Lilly in that business even as Wegovy and Ozempic remain central to its growth story. (thestar.com.my) Novo is also moving on the commercial and regulatory side of obesity treatment in the United Kingdom. The Medicines and Healthcare products Regulatory Agency approved a maximum Wegovy dose of 7.2 milligrams per week on January 6, 2026, for adults with obesity, and published that decision on January 16. (gov.uk) On April 14, Novo said British regulators also cleared a new single-dose injection device for that 7.2 milligram maintenance dose. The company said the new device replaces the earlier method of taking three 2.4 milligram injections together once a week. (pharmiweb.com) Novo’s statement said the OpenAI partnership is global, and CNBC reported the company framed it as a way to find therapies “still waiting to be discovered” for obesity and diabetes. The immediate test is whether faster analysis in the lab turns into drugs and delivery systems that reach patients sooner. (cnbc.com)
